Takeover

HLFHERBALIFE LTD.

Wholesale-Drugs, Proprietaries & Druggists' Sundries

Revenue
$5.0BFY2021: $5.8BFY2022: $5.2BFY2023: $5.1BFY2024: $5.0BFY2025: $5.0B
0.9% YoY
Operating margin
9.5%FY2021: 12.7%FY2022: 10.5%FY2023: 7.0%FY2024: 7.7%FY2025: 9.5%
24% YoY
EBITDA
$602MFY2021: $842MFY2022: $661MFY2023: $470MFY2024: $507MFY2025: $602M
19% YoY
Market cap
$1.4B
Employees
8,500
$593K revenue each
Net debt / EBITDA
2.2×
$1.3B net debt
AI in 10-K
1.6
mentions per 10K words

Takeover score 1 of 13

Fixable underperformance 0 of 7

Buyer economics 1 of 4

Catalysts 0 of 2

Financials

MetricFY2021FY2022FY2023FY2024FY2025YoYTrend
Revenue$5.8B$5.2B$5.1B$5.0B$5.0B 0.9% FY2021: $5.8BFY2022: $5.2BFY2023: $5.1BFY2024: $5.0BFY2025: $5.0B
Operating income$734M$545M$356M$386M$481M 25% FY2021: $734MFY2022: $545MFY2023: $356MFY2024: $386MFY2025: $481M
Net income$447M$321M$142M$254M$228M 10% FY2021: $447MFY2022: $321MFY2023: $142MFY2024: $254MFY2025: $228M
Operating cash flow$460M$353M$358M$285M$333M 17% FY2021: $460MFY2022: $353MFY2023: $358MFY2024: $285MFY2025: $333M
Capex$151M$156M$135M$122M$80M 34% FY2021: $151MFY2022: $156MFY2023: $135MFY2024: $122MFY2025: $80M
Stock-based comp$54M$44M$48M$50M$44M 12% FY2021: $54MFY2022: $44MFY2023: $48MFY2024: $50MFY2025: $44M
Buybacks$1.0B$147M$11M$8M$8M 1.2% FY2021: $1.0BFY2022: $147MFY2023: $11MFY2024: $8MFY2025: $8M

Deal filings

None.

13D filers

FiledFilerFormStakeIntent
May 6, 2021ICAHN CARL CSC 13D/A0.0%Passive
Jan 4, 2021ICAHN CARL CSC 13D/A3.9%Passive
Nov 5, 2020ICAHN CARL CSC 13D/A—Passive
Aug 17, 2020ICAHN CARL CSC 13D/A15.5%Active
Aug 12, 2020ICAHN CARL CSC 13D/A—Active
Oct 30, 2019ICAHN CARL CSC 13D/A19.1%Passive

Insider trading

Open-market buys, 12 mo
$182K · 4
Open-market sells, 12 mo
$3M · 4
Net
−$2M

Pay vs performance

No pay-versus-performance disclosure yet.